| 9.28 0.25 (2.77%) | 05-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.17  |
1-year : | 13.04 |
| Resists | First : | 9.56 |
Second : | 11.17 |
| Pivot price | 8.33 |
|||
| Supports | First : | 8.38 |
Second : | 7.65 |
| MAs | MA(5) : | 8.79 |
MA(20) : | 8.27 |
| MA(100) : | 9.44  |
MA(250) : | 11.46 |
|
| MACD | MACD : | 0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 88.9 |
D(3) : | 87.6 |
| RSI | RSI(14): 66 |
|||
| 52-week | High : | 18.89 | Low : | 6.65 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SPRY ] has closed Bollinger Bands are 0.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.57 - 9.6 | 9.6 - 9.63 |
| Low: | 8.97 - 9 | 9 - 9.04 |
| Close: | 9.22 - 9.27 | 9.27 - 9.33 |
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Wed, 06 May 2026
Earnings preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 earnings expected to decline - MSN
Fri, 01 May 2026
SPRY Technical Analysis | Trend, Signals & Chart Patterns | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill
Fri, 01 May 2026
SPRY Stock Price, Quote & Chart | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill
Wed, 29 Apr 2026
ARS Pharmaceuticals (NASDAQ: SPRY) sets 2026 meeting, highlights neffy launch and cash runway - Stock Titan
Thu, 23 Apr 2026
ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock? - Yahoo Finance
Fri, 17 Apr 2026
Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 99 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 16.2 (%) |
| Held by Institutions | 95 (%) |
| Shares Short | 26,760 (K) |
| Shares Short P.Month | 23,720 (K) |
| EPS | -1.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.14 |
| Profit Margin | -203.3 % |
| Operating Margin | -147.7 % |
| Return on Assets (ttm) | -33.1 % |
| Return on Equity (ttm) | -92.4 % |
| Qtrly Rev. Growth | -67.6 % |
| Gross Profit (p.s.) | 0.51 |
| Sales Per Share | 0.84 |
| EBITDA (p.s.) | -1.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -171 (M) |
| Levered Free Cash Flow | -95 (M) |
| PE Ratio | -5.34 |
| PEG Ratio | 0 |
| Price to Book value | 8.06 |
| Price to Sales | 10.93 |
| Price to Cash Flow | -5.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|